NEW YORK, NY / ACCESSWIRE / November 8, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Waitr Holdings Inc. (NASDAQ:WTRH)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/waitr-holdings-inc-loss-submission-form?prid=4284&wire=1
Lead Plaintiff Deadline: November 26, 2019
Class Period: on behalf of shareholders who purchased shares between May 17, 2018 and August 8, 2019, including, but not limited to, those who acquired Waitr shares in connection with the Going Public Transaction, and those who acquired shares of the Company in the May 2019 Secondary Offering.
Allegations against WTRH include that: (i) Waitr lacked a plan to achieve profitability and, contrary to the statements of Company founder Chris Meaux, Waitr was not at or near profitability and Defendants had created the illusion of financial stability by engaging in a host of illegal and improper activities each designed to inflate revenues and earnings-such as unilaterally breaking low-rate contracts and imposing significantly higher rates, and by refusing to pay drivers for mileage related expenses-both of which ultimately resulted in independent class action lawsuits; and (ii) Waitr's technology provided no real advantage and the Company could not obtain the developer, programming, or engineering resources necessary to enhance, maintain, and develop industry leading software from its headquarter location in Lake Charles, Louisiana.
Myriad Genetics, Inc. (NASDAQ:MYGN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/myriad-genetics-inc-loss-submission-form?prid=4284&wire=1
Lead Plaintiff Deadline: November 26, 2019
Class Period: September 2, 2016 to August 13, 2019
Allegations against MYGN include that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
UP Fintech Holding Limited (NASDAQ:TIGR)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/up-fintech-holding-limited-loss-submission-form?prid=4284&wire=1
Lead Plaintiff Deadline: January 6, 2020
Class Period: all persons and entities that purchased or otherwise acquired: (a) Fintech American Depository Shares pursuant and/or traceable to the Company's initial public offering conducted on or about March 20, 2019; or (b) Fintech securities between March 20, 2019 and May 16, 2019.
Allegations against TIGR include that: (i) Fintech was experiencing a material decrease in commissions because of a negative trend related to risk-averse investors in the market; (ii) Fintech was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (iii) Fintech was incurring significant additional expenses related to, inter alia, employee headcount and employee compensation and benefits; (iv) all of the foregoing had led to Fintech significantly increasing operating costs and expenses; and (v) as a result, the documents filed by the Company in connection with the initial public offering were materially false and/or misleading and failed to state information required to be stated therein, and the Company's Class Period statements were likewise materially false and/or misleading.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong